Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $25.54 billion. The enterprise value is $33.80 billion.
Important Dates
The last earnings date was Wednesday, February 11, 2026, before market open.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
Royalty Pharma has 577.24 million shares outstanding. The number of shares has decreased by -27.79% in one year.
| Current Share Class | 427.25M |
| Shares Outstanding | 577.24M |
| Shares Change (YoY) | -27.79% |
| Shares Change (QoQ) | -23.33% |
| Owned by Insiders (%) | 11.54% |
| Owned by Institutions (%) | 79.24% |
| Float | 375.48M |
Valuation Ratios
The trailing PE ratio is 24.62 and the forward PE ratio is 8.79. Royalty Pharma's PEG ratio is 0.85.
| PE Ratio | 24.62 |
| Forward PE | 8.79 |
| PS Ratio | 7.98 |
| Forward PS | 8.34 |
| PB Ratio | 2.96 |
| P/TBV Ratio | 4.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 10.36 |
| PEG Ratio | 0.85 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 43.83 |
| EV / Sales | 14.21 |
| EV / EBITDA | 21.61 |
| EV / EBIT | 21.66 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.93 |
| Debt / EBITDA | 5.73 |
| Debt / FCF | n/a |
| Interest Coverage | 5.06 |
Financial Efficiency
Return on equity (ROE) is 13.26% and return on invested capital (ROIC) is 5.34%.
| Return on Equity (ROE) | 13.26% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 5.34% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 5.56% |
| Revenue Per Employee | $23.78M |
| Profits Per Employee | $7.71M |
| Employee Count | 100 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.50% in the last 52 weeks. The beta is 0.42, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +39.50% |
| 50-Day Moving Average | 40.21 |
| 200-Day Moving Average | 36.97 |
| Relative Strength Index (RSI) | 73.55 |
| Average Volume (20 Days) | 4,016,460 |
Short Selling Information
The latest short interest is 27.51 million, so 4.77% of the outstanding shares have been sold short.
| Short Interest | 27.51M |
| Short Previous Month | 28.80M |
| Short % of Shares Out | 4.77% |
| Short % of Float | 7.33% |
| Short Ratio (days to cover) | 7.08 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.38 billion and earned $771.00 million in profits. Earnings per share was $1.80.
| Revenue | 2.38B |
| Gross Profit | 2.67B |
| Operating Income | 1.56B |
| Pretax Income | 1.32B |
| Net Income | 771.00M |
| EBITDA | 1.56B |
| EBIT | 1.56B |
| Earnings Per Share (EPS) | $1.80 |
Full Income StatementBalance Sheet
The company has $955.04 million in cash and $8.97 billion in debt, with a net cash position of -$8.01 billion or -$13.88 per share.
| Cash & Cash Equivalents | 955.04M |
| Total Debt | 8.97B |
| Net Cash | -8.01B |
| Net Cash Per Share | -$13.88 |
| Equity (Book Value) | 9.62B |
| Book Value Per Share | 14.95 |
| Working Capital | n/a |
Full Balance SheetMargins
Gross margin is 112.45%, with operating and profit margins of 65.60% and 32.42%.
| Gross Margin | 112.45% |
| Operating Margin | 65.60% |
| Pretax Margin | 55.68% |
| Profit Margin | 32.42% |
| EBITDA Margin | 65.75% |
| EBIT Margin | 65.60% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $0.94, which amounts to a dividend yield of 2.12%.
| Dividend Per Share | $0.94 |
| Dividend Yield | 2.12% |
| Dividend Growth (YoY) | 5.29% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 51.09% |
| Buyback Yield | 27.79% |
| Shareholder Yield | 29.89% |
| Earnings Yield | 2.99% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for Royalty Pharma is $47.75, which is 7.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $47.75 |
| Price Target Difference | 7.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 13.49% |
| EPS Growth Forecast (5Y) | 25.32% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
